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A esclerose múltipla (EM) é uma doença inflamatória crónica, desmielinizante e 
degenerativa que afecta o sistema nervoso central (SNC). Estima-se que mais de 2,5 
milhões de pessoas, na sua maioria jovens entre os 25 e os 40 anos de idade, sofram desta 
doença. A patologia da EM é caracterizada por uma inflamação multifocal no SNC, 
degeneração da baínha lipídica de mielina que reveste os axónios das células nervosas e 
formação de placas escleróticas que levam à destruição e perda de função dos mesmos. 
Estes processos prejudicam a comunicação entre os axónios, responsáveis pela condução 
dos impulsos eléctricos.  
A EM é uma doença heterogénea e envolve diversos processos imunopatológicos 
que se podem manifestar sob diferentes fenótipos clínicos incluindo formas de 
surto/remissão e formas progressivas. São várias as manifestações clínicas que 
caracterizam esta doença mas as principais são a perda de tónus muscular, rigidez articular, 
alterações visuais e descoordenação motora. Pouco se sabe sobre a etiologia da doença. 
Factores genéticos e ambientais são considerados importantes no desenvolvimento desta 
patologia. Diversos estudos sugerem que os mecanismos que levam à degeneração do 
SNC resultam de uma resposta inflamatória local caracterizada pelo recrutamento de 
linfócitos T helper, que reconhecem como estranhos os componentes da baínha lipídica da 
mielina contra os quais montam uma resposta imune. Posteriormente seguem-se 
mecanismos neurodegenerativos que caracterizam a perda dos axónios.  
Do ponto de vista imunológico, as células apresentadoras de antigénios (APC) 
residentes na periferia, especialmente as células dendríticas, são consideradas essenciais 
numa primeira activação dos linfócitos T helper que posterioremente migram para o SNC. 
Os linfócitos T helper podem ter acesso ao SNC após a disrupção da barreira 
hematoencefálica. A baínha de mielina fica assim exposta e os seus componentes são 
apresentados por células gliais do SNC aos linfócitos que são reactivados desencadeando-
se uma resposta inflamatória. Assim, indivíduos que possuem linfócitos T helper capazes de 
reconhecer algum desses componentes com grande avidez, apresentados de forma activa 
pelas APC no timo, poderão desenvolver EM. Os linfócitos activados são assim 
responsáveis pelo recrutamento de outras células do sistema imunitário e pela geração de 
uma resposta imunitária contra um determinado componente da mielina levando à sua 
destruição.   
A encefalomielite autoimune experimental (EAE) é um modelo animal de 
desmielinização do SNC e é amplamente utilizada como modelo experimental da EM. A 
EAE é fundamentalmente utilizada para estudar a componente inflamatória da EM. A EAE 
pode ser induzida em ratinhos geneticamente susceptíveis por imunização, utilizando 
antigénios de proteínas constituintes da mielina como por exemplo, myelin basic protein 
(MBP), proteolipid protein (PLP) ou myelin oligodendrocyte glycoprotein, emulsificados em 
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adjuvante, p.e. complete Freund’s adjuvant (CFA), um estímulo pró-inflamatório que activa 
os receptores das células do sistema imune inato. A administração da toxina proveniente de 
Bordetella pertussis (PTx) é também indispensável para o desenvolvimento da doença pois 
induz perturbações na permeabilidade da barreira hematoencefálica permitindo a entrada no 
SNC das células mediadoras da resposta imune. As manifestações clínicas da doença 
dependem essencialmente da estirpe de ratinho e do antigénio utilizado. Neste projecto 
utilizaram-se dois modelos: ratinhos do tipo selvagem e ratinhos transgénicos, ambos 
pertencentes à estirpe C57BL/6. O modelo transgénico foi criado de modo que a maioria das 
suas células T helper CD4+ (TH) expressassem receptores (TCR) com especificidade para o 
péptido formado pelos aminoácidos 35 a 55 da proteína MOG (MOG35-55) que é assim 
reconhecido com maior avidez tornando estes ratinhos mais susceptíveis ao 
desenvolvimento da EAE. Cerca de dez dias após a imunização com o pétpido MOG35-55 e 
adjuvantes, os ratinhos começam a manifestar os primeiros sintomas da doença que é 
caracterizada por uma paralisia ascendente classificada em cinco estádios: 1, flacidez da 
cauda; 2, fraqueza nos membros inferiores; 3, paralisia completa dos membros inferiores; 4, 
paralisia completa dos membros superiores e 5, morte.  
A heme oxigenase-1 (HO-1) é uma enzima conhecida pelo seu efeito protector no 
controlo das respostas imunes durante processos inflamatórios, como é o caso da EM. Esta 
enzima é expressa no SNC de pacientes com EM e em modelos experimentais da doença. 
A HO-1 é uma enzima induzida por vários factores de stress celular, que catalisa a 
degradação de grupos heme em ferro (Fe), biliverdina (BV) e monóxido de carbono (CO). 
Verificou-se que a ausência desta enzima aumenta a susceptibilidade à EAE. Estudos 
recentes demontram também que a indução farmacológica desta enzima com protoporfirina 
IX de cobalto (CoPPIX), após o aparecimento dos primeiros sintomas, tem um efeito 
protector na progressão da EAE e que tal depende da sua capacidade de inibir a expressão 
do complexo de histocompatibilidade classe II (MHC class II) nas APC, incluindo células 
dendríticas. Estudos anteriores mostram que as células dendríticas quando expostas a um 
estímulo de maturação p.e. lipopolissacárido (LPS) in vitro também expressam HO-1.  
Permanecia no entanto por determinar o mecanismo através do qual este efeito era 
exercido. Assim, testou-se a hipótese de, no contexto da EAE, a expressão de HO-1 em 
células dendríticas controlar as respostas efectoras dos linfócitos T helper de modo a inibir a 
progressão da EAE. De modo a testar-se a hipótese, estabeleceu-se uma nova técnica de 
indução de EAE que requer a transferência adoptiva de células dendríticas derivadas da 
medula óssea de ratinho e incubadas com o péptido MOG35-55. Em ratinhos do tipo selvagem 
da estirpe susceptível à EAE, os C57BL/6, não foi possível induzir a doença com este 
método e deste modo testar a hipótese proposta. Assim, usou-se o modelo de ratinho 
transgénico, os 2D2, para testar a hipótese em questão visto possuirem um maior número 
de linfócitos T helper específicos para MOG35-55. Verificou-se que os 2D2 são mais 
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susceptíveis ao desenvolvimento da doença pois, ratinhos imunizados apenas com CFA e 
PTx, dois estímulos pró-inflamatórios, desenvolvem EAE. Ratinhos imunizados com células 
dendríticas a apresentar MOG35-55 também desenvolvem EAE. No entanto, como o número 
de animais testados em cada grupo não é suficientemente grande para atingir significado 
estatístico não foi possível tirar conclusões acerca das diferenças na severidade da doença 
entre os dois grupos. Tendo isto em mente, as experiências realizadas levam a crer que 
ratos que receberam células dendríticas (Hmox1+/+) desenvolvem sintomas mais cedo e a 
doença tende a ser mais severa. Contudo, estes são apenas resultados preliminares e mais 
experiências serão necessárias para confirmar estas obervações. Será também necessário 
analisar se, de facto, células dendríticas Hmox1-/- induzem uma doença ainda mais severa. 
In vitro verificou-se que células dendríticas derivadas de ratinhos Hmox1+/+ e Hmox1-/-, após 
diferenciação e maturação, não apresentam diferenças significativas na expressão de 
moléculas de activação. Ficou também por testar o efeito da expressão de HO-1 em células 
dendríticas in vitro na activação e proliferação de linfócitos T helper quando comparadas 
com células dendríticas que não expressam HO-1. 
De um modo geral, os resultados obtidos sugerem que os ratinhos 2D2, serão um 
bom modelo para testar a hipótese descrita e compreender melhor alguns dos eventos 
iniciais da EAE despoletados por linfócitos T helper.  
  





















2. SUMMARY  
Multiple sclerosis (MS) is a chronic inflammatory disease that affects the central nervous 
system (CNS). It is estimated that over 2.5 million people, mainly young adults between 25 
and 40 years old, suffer from this disease. MS pathology is characterized by multifocal CNS 
inflammation, degeneration of the myelin sheath, surrounding the axons of neurons, and 
formation of “sclerotic plaques” that leads to axonal damage. The etiology of the disease 
remains unknown with genetic and environmental factors being important for its 
development. Mechanisms that lead to CNS degeneration result from a local inflammatory 
response characterized by the recruitment of T cells that recognize myelin peptides against 
which they mount an effector response. Heme Oxygenase-1 (HO-1) is a ubiquitously 
expressed stress-induced enzyme, responsible for the degradation of free heme into iron 
(Fe), biliverdin (BV) and carbon monoxide (CO). HO-1 controls inflammatory processes such 
as the ones associated with the development of MS. It is expressed in the CNS during MS as 
well as in experimental autoimmune encephalomyelitis (EAE), a murine model of MS. 
Deletion of HO-1 is associated with increased susceptibility to EAE, while pharmacological 
induction of its expression arrests EAE progression. The protective effect of HO-1 is 
associated with inhibition of expression of histocompatibility complex class II (MHC class II) 
on antigen presenting cells (APC), including dendritic cells (DCs). The main hypothesis 
tested in this project was that expression of HO-1 in DCs might modulate T cell responses in 
a manner that prevents the progression of EAE. We found that absence of HO-1 in DCs does 
not affect significantly its maturation by modulating the expression of surface activation 
markers. However, we failed to demonstrate whether this absence could afford any effect on 
the disease, when DCs are adoptively transferred into naïve mice, leading to a more severe 
outcome when compared to Hmox1+/+ DCs.  
 
  






3. INTRODUCTION  
3.1. INFLAMMATION AND IMMUNITY  
The human body is the constant target of pathogens and other harmful stimuli. A set of 
barriers such as the mucosal epithelia and the epidermis protect the organism and to a 
certain degree avoid invasion by pathogens. In higher mammals, these physical barriers are 
not sufficient to contain and prevent microbial infections. Mammals, including humans, have 
developed an immune system responsible for the recognition and clearance of foreign 
pathogens. Inflammation is the initial reaction triggered against microbial infection, leading to 
the activation of the immune system and ultimately to the removal of the initial eliciting 
stimulus, i.e. the pathogen.  
Inflammation was first defined by Celsus, in AD40, by the four classical signs “rubor, 
calor, tumor e dolor” (redness, heat, swelling and pain). The entire process comprises three 
distinct phases: initiation, amplification and resolution, each one characterized by different 
mediators, working in a coordinate manner to eradicate the source of injury and to promote 
return to homeostasis, once the eliciting stimulus is removed. There are, however, situations 
in which the mechanisms involved in the resolution of inflammatory responses are 
deregulated leading to a chronic inflammatory state that can lead to irreversible tissue 
damage. Nonetheless, in most cases, inflammation should be considered as a beneficial and 
protective process against noxious stimuli, while promoting tissue regeneration. Inflammation 
is also critical to trigger immunity that is to elicit protective responses against pathogens and 
avoid in this manner the deleterious effects associated with infection. In higher mammals 
there are two types of immune responses, the innate and the adaptive (reviewed in (1)).  
3.1.1. INNATE IMMUNITY 
The innate immune system is the first line of defense against invading pathogens and is 
comprised of cells that express germline encoded pattern-recognition-receptors (PRR) with 
specificity to molecular structures shared among different microorganisms (2) and known as 
PAMPs (pathogen-associated molecular patterns) (3). Self-molecules have also molecular 
patterns that can be recognized by these PRR, which raises important questions as to the 
ability of innate immunity to differentiate between self and non-self stimuli. Toll-like receptors 
(TLRs) are so far the best characterized family of PRR (reviewed in (4)). They are 
transmembrane receptors expressed in so called innate immune cells such as mast cells, 
eosinophils, basophils, neutrophils, natural killer (NK) cells, macrophages (Mø) and dendritic 
cells (DCs) (reviewed in (1, 5)). Signaling via PRR activates intracellular signal transduction 
pathways ultimately leading to regulated expression of genes encoding proinflammatory 
mediators such as chemokines, cytokines and adhesion molecules. Sustained expression of 




3.1.1.1. DENDRITIC CELLS (DCS) 
Due to their ability to interact with and regulate the activation of cells of the adaptive immune 
system, DCs play a key role in bridging innate and adaptive immunity. DCs are professional 
antigen presenting cells (APC) specialized in capturing, processing and presenting antigens 
(Ag) that are substances recognized as foreign by the organism and that can elicit an 
immune response. Ag are recognized by receptors of the adaptive immune system (see 
Adaptive immunity, section 
3.1.2.) when presented in the 
context of surface major 
histocompatibility complex 
(MHC) class I or II (6). To 
present Ag efficiently, DCs 
must first be activated, which 
occurs through engagement of 
PRR when these recognize 
PAMPs. Signaling via these 
PRR induces DCs to produce 
cytokines and express cell-
surface molecules as well as to 
migrate to the secondary lymph 
nodes where adaptive immune 
responses are initiated. DCs are the only cells described with capacity to activate naïve T 
cells being much more efficient APC than other cell types such as Mø and/or B cells (7). DCs 
originate from either myeloid or lymphoid precursors and reside in the majority in peripheral 
tissues (reviewed in (1)) where they sample the environment and capture antigens. While 
DCs are clearly responsible for the recognition and uptake of pathogens to be presented to 
cells of the adaptive immune system, priming in this manner adaptive immune responses, 
they are also able to induce tolerance (reviewed in (8)), a term that defines broadly a series 
of cellular and molecular mechanisms by which cells of the adaptive immune system are 
functionally inactivated (by deletion, induction of anergy or acquisition of regulatory 
functions).  
Under homoeostatic conditions, DCs are maintained in an immature state in 
peripheral tissues. Immature DCs have a high capacity to internalize and process exogenous 
Ag (reviewed in (9)) but reduced capacity to prime an adaptive immune response, being 
more prone to induce tolerance instead. Microbial products can signal through TLRs, 
expressed both in the outer and inner membranes of DCs, leading to their activation, a 
phenomenon associated with the upregulation of a series of molecules that are required to 
activate cells of the adaptive immune system. At the same time, mature DCs lose the ability 
                                                                                                               
Adapted from Reis e Sousa, C. 2006. Nature Immun. Reviews 6, 476-483 
Figure 1. DC maturation. Immature DCs can internalize and process 
antigens but are inefficient in priming immune responses. Maturation 
induced by exogenous signals such as LPS leads to an increase in DC 
immunogenicity and downregulation of antigen acquisition and processing. 
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to capture and process Ag (Fig. 1). Despite their protective role in immunity, when DCs 
function is not properly regulated, these cells can be critically involved in the pathogenesis of 
many medical conditions such as those leading to autoimmune diseases (see Autoimmunity, 
section 3.2) or allergy (10).   
3.1.2. ADAPTIVE IMMUNE SYSTEM 
Adaptive immunity is characterized by increased specificity of the response generated 
against a given antigen as well as by the capacity to distinguish between self/non-self. Ag 
receptors of adaptive immune cells are encoded by gene segments that undergo somatic 
recombination which enables the generation of receptors with a very large spectrum of 
recognition, the immune repertoire (11). In other words, somatic recombination of receptors 
from the adaptive immune system allows the recognition of a tremendous diversity of the 
antigens and allows B and T cells, the main mediators of adaptive responses, to recognize 
and distinguish subtle differences among microorganisms. Because these adaptive Ag 
receptors are expressed by T and B cells, they are referred to as T-cell and B-cell receptors, 
i.e. TCR and BCR, respectively. Upon engagement of the TCR or BCR, lymphocytes 
mediate effector responses via different mechanisms. In T cells, the TCR is kept within the 
surface of the cells and the effector response is mediated through the secretion of 
chemokines, cytokines as well as effector molecules that destroy the pathogens. Because 
this type of response involves the activation of Mø, NK cells and citotoxic T cells (TC), it is 
known as cell-mediated immunity. In the case of B cells, the Ag receptor can be secreted 
allowing to bridge immune recognition to effector function via soluble molecules and 
receptors on cell surfaces that bind specifically to soluble Ag, the antibodies. These 
antibodies are contained in body fluids (once termed humors) and as such this is called 
humoral immunity (reviewed in (1)). The function of B cells is beyond the scope of this thesis 
and will not be further discussed.  
3.1.2.1. T CELLS  
T cells arise from hematopoietic precursors in the bone marrow and migrate to the thymus 
where they undergo negative selection. A process via which T cells that express TCR with 
high avidity to self-antigens are deleted as to avoid auto-reactivity and consequently the 
development of autoimmune diseases (12). T cells that recognize self-antigens with low 
avidity survive and differentiate into mature T cells. Mature T cells can be divided in three 
subpopulations: T helper (TH), T cytotoxic (TC) and T regulatory (TReg) cells. TH cells express, 
on the cell surface, the glycoprotein CD4 whereas TC cells express the CD8. Both act as co-
receptors for the TCR (13).  
TH cells recognize antigens presented by APC, mainly DCs, when these are 
presented in the context of an MHC class II molecule. Along with Ag presentation, 
costimulatory molecules expressed by mature DCs are recognized by specific ligands 
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expressed in naïve T cells. These 
molecules provide signals required 
to promote TH cell activation, 
proliferation or alternatively anergy 
or even death. Depending on the 
profile of cytokines and 
costimulatory molecules expressed 
by APC, naïve TH cells that have 
engaged their TCR can differentiate 
and give rise to three different TH 
lineages of effector cells that differ 
in the target and type of immune 
response they elicit.  
For more than twenty years 
it has been well accepted that TCR 
engagement by MHC class II molecule presenting a peptide leads to naïve T cell 
differentiation into two major functional subtypes, TH1 and TH2 (14). This is known as the 
TH1/TH2 paradigm. It is also well accepted that this fate decision is dictated by APC, and in 
particular DCs. Upon TLR ligation and signaling, DCs express a set of surface costimulatory 
molecules and cytokines that acts as key instructors for TH cell differentiation. Upon 
differentiation, TH cells can secrete specific sets of proinflammatory cytokines, which direct 
the effector immune response. TH1 cells secrete predominantly IL-2, TNF-α and IFN-γ, and 
elicit immune responses against intracellular pathogens by controlling cell-mediated 
functions such as Mø activation. TH2 cells secrete IL-4, IL-5 and IL-13 stimulating B cell 
activation and humoral immunity (15, 16) (Fig. 2). TH cell differentiation towards a TH1 
phenotype suppresses differentiation into a TH2 phenotype and vice-versa ((17) and 
reviewed in (15)). Both TH1 and TH2 cells can play a central role in the development of organ-
specific autoimmune diseases. 
Recently, a new TH cell lineage has been identified, the TH17 cells, that express IL-17 
as signature cytokine (18, 19). This finding has created the need to reformulate the TH1/TH2 
paradigm (15, 20). The target of the effector function exerted by the TH17 cells lineage is not 
entirely clear but seems to be extracellular pathogens in epithelial surfaces (Fig. 2). TH17 
cells seem to play a critical role in the pathogenesis of several autoimmune diseases such as 
MS and rheumatoid arthritis (RA) that were previously thought to be mediated mainly by TH1 
cells (18, 21) (see Autoimmunity, section 3.2.).  
TReg are the main mediators of peripheral immune tolerance, a mechanism ensuring 
that immune reactions against self-antigens are repressed and thus autoimmune responses 
prevented. TReg help restore homeostasis upon infection events. Several mechanisms via 
 
                                        From Medznhitov R., 2007. Nature, 449, 819-826 
Figure 2. TH cell differentiation. Naïve TH cells can differentiate into 
effector TH1, TH2 and TH17 cells.  Each type of effector TH cell is 
characterized by a specific profile of cytokine secretion and by distinct 
effector mechanism as illustrated in the figure. 
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which these cells mediate host defense/protection have been proposed, although a unified 
mechanism of action remains controversial. Naturally occurring TReg differentiate in the 
thymus, express the transcription factor forkhead box P3 (FoxP3) and are classically defined 
by their constitutive expression of CD25 (also known as the IL-2 receptor α-chain). Aside 
from the thymus, in the periphery, conventional CD4+ TH cells can be induced to become 
Foxp3+ and thus mediate regulatory functions as well. Signals provided by DCs, as well as by 
regulatory cytokines, are important for the induction of this phenotype (reviewed in (22, 23)). 
A delicate balance of cytokines promotes the differentiation of naïve CD4+ TH cells into either 
polarized TH17 cells or TReg (20). 
3.2. AUTOIMMUNITY 
Autoimmunity is the failure of an organism to recognize its own constituent parts as "self", 
which results in the generation of an effector immune response against its own cells and 
tissues, i.e. self. Any disease that results from an effector immune response against self-
antigens is referred to as an autoimmune disease. Multiple sclerosis (MS) is one of such 
diseases that targets Ag expressed specifically in the CNS.  
3.2.1. MULTIPLE SCLEROSIS (MS): AN OVERVIEW 
MS is a chronic inflammatory disease of the human CNS that affects over 2.5 million people 
worldwide (24, 25). Several subtypes, or patterns of progression, have been described (Fig. 
3). Most of individuals suffering from MS undergo relapsing-remitting events (acute phase) 
that, to a certain extent, can culminate in the re-establishment of neurological functions (26). 
MS is mediated primarily by self-reactive TH cells that orchestrate an attack directed against 
components of the myelin sheath that surrounds axons of neurons followed by, in a latter 
stage, neurodegenerative processes. Pathological manifestations are characterized 
essentially by infiltration of inflammatory mediators, demyelination, and axonal damage 
leading to progressive neurologic disability (27). 
3.2.1.1. ANIMAL MODELS AND IMMUNOPATHOGENESIS OF MS 
To help dissect and gain further knowledge on the pathological mechanisms underlying MS, 
several animal models have been generated. The murine model of experimental autoimmune 
encephalomyelitis (EAE) can be induced by immunization with CNS-derived antigens such 
as the myelin basic protein (MBP) (28), proteolipid protein (PLP) (29) and myelin 
oligodendrocyte glycoprotein (30). The pathological mechanisms and clinical progression 
depends on the genetic background of the animal (31) and on the antigen used (32). The use 
of proinflammatory adjuvants such as complete Freund’s adjuvant (CFA), which contains 
heat-inactivated Mycobacterium tuberculosis, is crucial for disease induction (25, 33). The 
molecular explanation for this is that CFA can trigger PRR signaling in DCs and lead to self-
antigen presentation to self-reactive TH cells. In some mouse strains the use of Pertussis 
toxin (PTx) derived from Bordetella pertussis must be provided so that blood brain barrier 
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(BBB) disruption can occur and 
allow the access of immune cells 
to the CNS, ultimately leading to 
the development of the disease 
(34).  
Immunization of C57BL/6 
mice with MOG35-55 peptide 
emulsified in CFA and 
administration of PTx leads to a 
disease that shares clinical and 
histopathological similarities with 
MS. The first signs of disease 
are observed usually 10 days post immunization leading to a monophasic disease 
characterized by an ascending paralysis starting at the tail and followed by the limbs, 
resulting from interruption of motor and sensory nerve impulses that can culminate in death 
or spontaneous recovery (reviewed in (35)). There are other murine models of EAE that do 
not require CNS antigen immunization to trigger disease, such as the TCR transgenic mouse 
for the MOG35-55 antigen on the C57BL/6 background, i.e. 2D2 mice (28). 2D2 mice develop 
optic neuritis spontaneously, a hallmark of MS patients (32). More than 98% of T cells in 
these mice express a TCR that recognizes specifically the MOG35-55 peptide and therefore 
the mice are more prone to spontaneous development of autoimmunity. However, only a 
small percentage, about 4%, of these mice develops EAE spontaneously.  
Acute lesions, both in MS and EAE were though to be initiated by TH cells mainly TH1 
cells. This notion was largely based on the observations that i) CNS infiltrating TH cells 
express IFN-γ (36), a TH1-derived cytokine that is associated with the onset of EAE (37) and 
that ii) EAE can be induced by adoptive transfer of encephalitogenic TH1 cells (38). More 
recently however, the TH17 subset has been proposed to be the main effector T cell lineage 
involved in the pathogenesis of EAE and presumably in that of MS as well (39, 40). 
Supporting evidences for this notion came from the observations that i) IL-17 levels are 
elevated in the CNS of MS patients (41), ii) neutralization of IL-17 by specific antibody 
treatments in vivo prevents the induction of EAE (reviewed in (42)) and iii) mice that lack IL-
6, one of the main cytokines responsible for TH17 lineage commitment, do not develop EAE 
(43). 
DCs are key players during the initiation and progression of EAE. As for the activation 
of non-pathogenic TH cells, myelin-specific TH cells require three types of signals provided by 
DCs to become pathogenic. The first involves presentation of the antigen in MHC class II 
context in order for the TH cell to recognize its cognate antigen through TCR. The second 
leads to activation and expansion of the T cell population and involves interaction of CD80 
  
Figure 3. Clinical course of 
Multiple sclerosis. 
Relapsing-remitting MS is 
characterized by unpredictable 
attacks followed by disease 
inactivity where the patient might 
recover slightly, i.e. remission. 
Primary progressive MS is 
characterized by steady increase 
of disability following the initial MS 
onset. There are no periods of 
remission. Secondary progressive 
MS is characterized by initial 
relapse-remitting disease 
changing suddenly into primary 
progressive. Progressive 
relapsing MS is progressive from 
the start with acute symptom flare-
ups, but may have some relapses 




and CD86 costimulatory molecules expressed by DCs with CD28 on the surface of T cells. 
The third is provided by the secretion of cytokines by DCs, which directs the differentiation of 
naïve TH cells into an effector T cell subtype (see T cells, section 3.1.2.1.). Encephalomyelitic 
TH cells are activated in the lymph nodes and migrate to the CNS, where they induce 
changes in endothelia, allowing access across the BBB into the CNS (reviewed in (24)). 
Under homeostatic conditions, the BBB protects the CNS from invasion of immune 
competent cells (30). However, when encephalomyelitic TH cells migrate into the perivascular 
space (PVS), i.e. the space between blood vessels in the CNS and the parenchyma, they 
can be reactivated upon interaction with resident DCs, that present the Ag derived from 
myelin leading the TH cells to enter the CNS parenchyma where they can proliferate. Signals 
provided by these DCs allow TH cells to acquire their effector function (TH1/TH17), secreting 
proinflammatory cytokines (IFN-γ/IL-17). TH cells also activate the CNS microglia that further 
recruits Mø, B cells, TC and other inflammatory cells. Activated microglia promotes 
demyelination, which can culminate in axonal/neuronal damage. 
Inflammatory-mediated conditions, such as those involved in MS pathology, have 
activated regulatory mechanisms that control the immune responses and protect tissues from 
injury (44). Cytoprotective genes are believed to play an important role in such mechanisms 
by dampening inflammation. One of such genes is heme oxygenase-1 (Hmox1) that has anti-
inflammatory (45) and anti-apoptotic (46) properties.  
3.3. THE HEME OXYGENASE (HO) SYSTEM 
HOs are the rate-limiting enzymes in the catabolism of free heme (47). This catalytic system 
requires the combination of NADPH and cytochrom P450 reductase (Fig. 4). Heme 
degradation by HO enzymes generates equimolar amounts of free iron (Fe), biliverdin (BV), 
which is converted to bilirubin by biliverdin reductase (BVR) and the gas carbon monoxide 
(CO) (47). Three distinct isoforms of HO have been described to date: HO-1, HO-2 and HO-
3. This last isoform, however, is not functional and is probably a pseudogene (48). HO-1 and 
HO-2 display highly conserved secondary structures but different expression patterns. Under 
homeostatic conditions HO-2 is constitutively expressed in most cell types, while HO-1 is 
only expressed in kupffer cells (liver) and Mø from spleen (red pulp) (49). Under 
inflammatory conditions HO-1 expression is strongly inducible in many cell types while that of 
HO-2 is not. HO-1 expression can be induced by stimuli that generate reactive oxygen 
species (ROS), which leads to the suggestion that HO-1 acts as a protective gene by eliciting 
a set of responses against the deleterious effects of ROS. The protective effect afforded by 
HO-1 is mediated via the products derived from heme catabolism. For instance, Fe2+ up-
regulates the expression of Fe-transporter pump that removes Fe from the cells (50) and 
induces ferritin expression that affords anti-oxidant protection by chelating free-iron, involved 
in ROS generation by the Fenton reaction (45). Biliverdin can be converted into bilirubin, a 
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potent antioxidant that scavenges peroxy radicals and inhibits lipid peroxidation (51). Finally, 
CO has potent anti-inflammatory properties as well (45, 52, 53). 
3.3.1. HO-1 IN MS AND EAE 
HO-1 is expressed during the 
development of MS (54) as well 
as that of EAE (55). A growing 
body of evidence suggests that 
expression of HO-1 has potent 
protective effects in EAE (52, 56). 
Hmox1-deficient C57BL/6 mice 
develop a more severe form of 
EAE when compared with wild-
type (Hmox1+/+) mice and 
pharmacological induction of HO-
1 after EAE onset, arrests disease 
progression and reverts its clinical 
outcome. The protective effect of HO-1 is associated with inhibition of MHC class II 
expression on DCs as well as with inhibition of proliferation and effector function of TH and TC 
cells in the CNS (52).  
When exposed to proinflammatory stimulus such as PRR agonists e.g. LPS, DCs 
upregulate the expression of HO-1. As referred to above, DCs shape TH cell effector 
responses, influence the outcome of inflammatory responses in models of autoimmune 
diseases and in particular in EAE, where they are implicated in the initial priming of myelin-
reactive TH cells present in lymphoid organs that migrate thereafter to the CNS. As 
pharmacological induction of HO-1 in DCs suppresses DC maturation, down regulating the 
expression of MHC class II (52) we asked whether expression of HO-1 in DCs could have a 
protective effect in the context of EAE.  
4. AIM OF THE PROJECT 
Data from our laboratory suggests that one of the mechanisms underlying the protective 
effects of HO-1 in the context of EAE is associated with a profound down modulation of self-
reactive TH cell activation (52). Based on this, we hypothesized that HO-1 expression in DCs 
might modulate TH activation/differentiation in a manner that suppresses the onset and 
progression of EAE. The expectation being that expression of HO-1 in DCs that present 
myelin derived peptides in the context of MHC class II, might interfere with the generation of 
a TH1/TH17 type of response that leads to the pathogenesis of autoimmune 
neuroinflammation.  
 
Figure 4. Heme catabolism by heme oxygenase-1. HO-1 catalyses 
heme degradation into three products: carbon monoxide (CO), biliverdin 
and Fe2+. Nicotinamide adenine dinucleotide phosphate (NADPH) and 
cytochrome P450 reductase are required for this reaction. Biliverdin is 
converted to bilirubin by biliverdin reductase and Fe2+ up-regulates the 




5.1. GENERAL APPROACH 
We have generated mouse dendritic cells (DCs) ex vivo from hematopoietic precursors 
present in the bone marrow (BM). These DCs were adoptively transferred into naïve 
recipients and analyzed for their ability to trigger autoimmune neuroinflammation. By 
comparing the effect of DCs that express or not HO-1, one should be able to assess whether 
HO-1 expression in DCs modulates TH cell responses involved in the pathogenesis of 
autoimmune neuroinflammation. The approach relies on setting-up the experimental 
conditions allowing DCs to initiate the pathogenesis of autoimmune neuroinflammation upon 
adoptive transfer into naive recipients. 
5.2. GENERATION AND CHARACTERIZATION OF MURINE DCS 
When cultured ex vivo in the presence of granulocyte monocyte-colony stimulating factor 
(GM-CSF) BM hematopoietic precursors generate large quantities of immature DCs (57). 
DCs generated in this manner retain an immature phenotype, i.e. high capacity to uptake 
antigen, low levels of costimulatory molecules, i.e. CD40, CD80, CD86, and MHC class I/II 
expression. When exposed to a PRR agonist, such as bacterial LPS, BM-derived immature 
DCs upregulate expression of all these activation markers and are referred to as mature 
DCs.  
BM hematopoietic precursors were cultured ex vivo in medium supplemented with 
GM-CSF and differentiated into CD11c+ cells, i.e. immature DCs. Briefly, BM cells were 
isolated from the femurs and tibiae of C57BL/6 mice and cultured for 7 days in Iscove’s 
modified Dulbecco’s medium (IMDM). Fresh medium supplemented with 1% GM-CSF was 
added according to the standard protocol (see Materials and Methods, section 8.3.2.), as 
illustrated in the schedule in Fig. 1A. This approach allowed for the generation of about 60 to 
70 x 106 cells per mouse at the end of the culture period. DC purity and maturation status 
were assessed by flow cytometry using CD11c (a DC marker) and CD40 (a marker of DC 
maturation) antibodies, respectively. Dead cells were excluded using propidium iodide (PI) 
staining. About 60% of live cells, stained negative for PI, were CD11c+ (Fig. 1B). This meant 
that the culture was not composed of DCs only with other cell types being present as well. 
Nevertheless, we thought that this mixed population would be sufficient as to test our 
hypothesis. We assessed CD40 expression level and since the cells had not been exposed 
to maturation stimuli we considered this level as being the basal.  
We then asked whether DCs could be induced to mature using a standard PAMP 
such as bacterial LPS. Exposure to increasing concentrations of LPS (from 0.1 to 1000 
ng/ml), for a period of 24 hours, triggered DC maturation as revealed by a significant 
upregulation of surface CD40 expression (Fig. 1C). The effect of LPS was dose dependent in 
that higher concentrations of LPS led to higher levels of CD40 expression. The percentage of 
CD11c+ DCs expressing high levels of CD40 (mature), increased from about 10% in non-
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treated DCs to 80% in DCs exposed to LPS (1000 ng/ml). Cell death was considered 
neglectable, about 7% at the highest LPS concentration used, i.e. 1000 ng/ml.  
5.3. INDUCTION OF EAE BY ADOPTIVE TRANSFER OF DCS INTO C57BL/6 MICE 
We next aimed at testing whether BM-derived DCs loaded with the CNS peptide MOG35-55 
(30) could induce the autoimmune disease EAE.  We used initially a previously published 
method in which DCs presenting the self-peptide MOG35-55 in the context of MHC class II 
induced EAE upon adoptive transfer into naïve C57BL/6 mice. It is worth noticing however 














The report by Weir et al. (58) suggested that adoptive transfer of DCs presenting MOG35-55 
can induce EAE in C57BL/6 mice when provided in combination with CFA and PTx. Another 
report by Dittel et al. (59) suggested that DCs loaded with MBP-Ac1-11 peptide and adoptively 
transferred into the genetically susceptible strain, B10.PL, could prime for EAE but only if, in 
addition, mice received naïve MBP Ac1-11-specific transgenic TH cells. Given the above, we 
tested whether BM-derived DCs matured with LPS and loaded with MOG35-55 peptide could 
induce EAE upon adoptive transfer into naïve C57BL/6 mice. Since this method is not widely 
used to induce EAE, we first tried repeating the exact same method used by Weir et al. and 
reproduce the data reported by these authors. The main difference in this protocol is in the 
period of exposure to LPS, i.e. 24h in our study versus 48h in the study of Weir et al. (58). 
BM-derived DCs were exposed to LPS (1000 ng/ml; 48h) loaded with MOG35-55 peptide (100 
µg/ml; 4-6h) and adoptively transferred into naïve mice (Fig. 2A). Exposure to LPS led to an 
increase in the percentage of DCs expressing high levels of maturation markers, i.e. MHC 
class II (8.7% in naïve vs. 46.3% in LPS-treated), CD80 (1.39% in naïve vs. 9.8% in LPS-
treated), CD86 (19.7% in naïve vs. 48.1% in LPS-treated) and CD40 (10.9% in naïve vs. 
53.6% in LPS-treated) (Fig. 2B). These DCs were adoptively transferred, i.e. 6 x 105 (Group 
2, n=5) or 12 x 105 (Group 3, n=5), intravenously (i.v.) into naïve female C57BL/6 mice that 
 
Figure 1. BM-derived 
CD11c+ cells upregulate the 
expression of CD40 upon 
LPS stimulation. BM-derived 
DCs were exposed to 
increasing concentrations of 
LPS and analyzed 24h 
thereafter by flow cytometry. 
(A) Schedule used to 
generate DCs from BM 
progenitors.  (B) Expression 
of CD11c in the live cell 
population (PI-). (C) 
Expression of CD40 in 
CD11c+ live PI- cells before 
(non-treated) and after LPS 
stimulation (D) Dead cells 
(PI+) inside the CD11c+ 
population in the higher dose 
of LPS (1000 ng/ml). Data is 
representative of one 
experiment. All values are %. 
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were further injected subcutaneously (s.c.), in both flanks, with CFA. Two days after, mice 
received PTx (i.v.). The control group (Group 1, n=5) received only CFA and PTx. Mice were 
followed daily for the appearance of clinical signs of EAE, during 30 days thereafter. None of 
the animals developed clinical symptoms of EAE (see Supplementary Table 1 in Annex, 
Results). We reasoned that this could be due to i) the relatively low number of DCs 














5.4. DCS LOADED WITH MOG35-55 PRIOR TO STIMULATION WITH LPS ARE POTENT INDUCERS OF TH 
CELL PROLIFERATION IN VITRO 
In order to boost DC immunogenicity, cells were loaded with the MOG35-55 peptide a few 
hours before maturation, i.e. stimulation with LPS. The reason for this being that DC 
maturation down-regulates Ag uptake and processing capacity (60). DCs immunogenecity 
was tested using as a read out their ability to induce the proliferation of anti-MOG35-55-
reactive TH cells in vitro. TH cells were isolated from inguinal and popliteal lymph nodes of 
C57BL/6 mice after footpad immunization (s.c.) with MOG35-55 peptide emulsified in CFA, 7 
days before. TH cells were purified as described in Materials and Methods (see section 
8.4.3.). The proliferative response of these anti-MOG35-55-reactive TH cells was analyzed in 
the presence of DCs treated as depicted in Fig. 3A. Cells were incubated in a 1:10 DC to TH 
cell ratio (10 x 103 DCs to 100 x 103 TH cells). Proliferation of responder TH cells was 
assessed by 3H-thymidine incorporation (see Material and Methods, section 8.4.5.) as 
depicted in Fig. 3B. When incubated with the MOG35-55 peptide, purified TH cells (in the 
absence of DCs) failed to proliferate (1312.6 ± 116.8 cpm) (Fig. 3B; experimental condition 
A). When incubated with the MOG35-55, TH cells in lymph nodes (containing TH cells, B cells 
and DCs) proliferated extensively (Fig. 3B; experimental condition B) (P = 0.028; A vs. B). 
This data illustrates the requirement of DCs to support the proliferation of anti-MOG35-55 TH 
cells. When added to immature DCs loaded with the MOG35-55 peptide (Fig. 3B; experimental 
condition C), TH cells also failed to proliferate (4687 ± 422.8 cpm) (P = 0.032; C vs. B). This 
Figure 2. Mature DCs express high 
levels of costimulatory molecules. (A) 
Scheme illustrating the schedule used to 
derive DCs from mouse BM (B) FACS 
analysis of DCs treated (black line) or 
not (solid gray) with LPS (1000 ng/ml; 
48h). DC were loaded with MOG35-55 
(100 µg/ml; 4 -6h) and stained for MHC 
class II, costimulatory molecules (CD40, 
CD80 and CD86) and myeloid 
differentiation marker CD11c. PI staining 
was used to exclude dead cells. (C) Cell 
death (PI+). Data is representative of 
one experiment. All values are %. 
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indicates that proliferation of anti-MOG35-55 TH cells requires DCs to be first activated by a 
PRR agonist such as LPS. We then tested different timings (24 and 48h) and concentrations 
of LPS stimulation (10, 100 and 1000 ng/ml) as well as pulsing with MOG35-55 (100 µg/ml) 















The results obtained suggest that TH cells proliferated more extensively when exposed to 
mature DCs (exposed to LPS) as compared to immature DCs (not exposed to LPS). By 
comparing the fold increases in TH cells using all the permutations described under Table 1, 
we conclude that maximal TH cell proliferation was obtained when MOG35-55 was added to 
DCs before exposure to LPS. We have used the experimental condition 2 to test whether 















Table 1. TH cell proliferation. 
 24h LPS (ng/ml) 48h LPS (ng/ml) 
CONDITIONS 10 100 1000 10 100 1000 
1 9.1 12.5 13.9 - - - 
2 12.6 13.9 10.0 - - - 
3 9.6 6.3 7.2 - - - 
4 - - - 12.5 12.0 11.5 
5 - - - 11.2 8.6 8.7 
6 - - - 6.2 5.7 4.3 
Legend: Fold increases in TH cell proliferation upon treatment of DCs in different conditions (1 to 6 from figure 3) vs. non-
treated DCs (4687 ± 422.8 cpm). (1) MOG35-55 was added to DCs (100 µg/ml; 4-6h) before LPS (10, 100 or 1000 ng/ml; 24h). 
DCs were co-cultured with TH cells and MOG35-55 was added thereafter (72h). (2) same as (1) but no MOG35-55 added after co-
culture of DCs with TH cells. (3) DCs were treated with LPS (10, 100 or 1000 ng/ml; 24h), loaded with MOG35-55 (100 µg/ml; 4-
6h) and co-cultured with TH cells. No MOG35-55 was added thereafter. (4-6) same as (1-3) but DCs were exposed to LPS for 
48h.  
Figure 3. DCs loaded with MOG35-55 before stimulation with LPS are potent activators of MOG35-55-reactive TH cells.  
(A) Scheme illustrating the schedules used to treat DCs before TH cell proliferation assay. BM derived DCs were cultured in 
different conditions (1-6) for 7 days and exposed to TH cells purified from the lymph nodes of mice, 7 days after MOG35-55 
immunization. (B) TH cell proliferation was determined by [3H] thymidine incorporation in triplicate wells in a 72h proliferation 
assay. Mean basal proliferation counts (T cells alone) were subtracted from the mean proliferation counts of each condition. 
Results shown are mean ± SD from triplicate wells. * P < 0.05. 
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We saw that using 24h of exposure to LPS, DCs death was reduced when compared to 48h 
(8% vs. 30%) and also because MOG35-55 was not kept on culture in this condition, it 
characterized better what we do in vivo that is to wash DCs before adoptive transfer into 
mice. We then tested whether in vitro MOG35-55 loaded DCs that were matured with LPS 
could induce EAE upon adoptive transfer in vivo. To this aim, MOG35-55-loaded DCs (100 
µg/ml; 4-6h plus LPS 1000 ng/ml; 24h) were adoptively transferred (1, 2 or 4 x 106 DCs; i.v. 
and i.p.) into 6 to 8 week-old naïve female mice (n=5 per group) (Fig. 3; experimental setting 
2).  
DC maturation was confirmed by FACS analysis before adoptive transfer. Percentage 
of mature DCs increased significantly upon LPS treatment, i.e. CD40high, CD80high and 
CD86high when compared to non-treated DCs (Fig. 4). Again, no clinical symptoms of EAE 
were observed during the 30 days that followed the adoptive transfer of activated DCs.  
 
5.5. COMPARISON OF HMOX1+/+ VS. HMOX1-/- DCS IN THE INDUCTION OF EAE UPON ADOPTIVE 
TRANSFER INTO C57BL/6 MICE 
Since EAE could not be induced upon adoptive transfer of DCs isolated from Hmox1+/+ mice, 
we decided to proceed by testing whether adoptively transferred DCs from Hmox1-/- C57BL/6 
mice would induce EAE. The hypothesis tested being that lack of HO-1 expression in DCs 
would modulate their immunogenicity in a way that would promote TH cell activation and 
ultimately the development of disease. DCs were derived from the BM of 6 to 12 week-old 
Hmox1+/+ and Hmox1-/- mice under the same experimental conditions as described in section 
5.4. At day 6, DCs were loaded with MOG35-55 peptide (100 µg/ml; 4-6h) and exposed 
afterwards to bacterial LPS (1000 ng/ml; 24h) to promote DC maturation. Percentage of 
mature DCs, i.e. expressing high levels of maturation markers, i.e. CD40, CD80, CD86 and 
MHC class II increased significantly in LPS treated DCs when compared with non-treated 
DCs both in Hmox1+/+ and Hmox1-/- population (Fig. 5).  There are no significant differences 
in the expression of the maturation markers in DCs derived from Hmox1+/+ versus Hmox1-/-, 
suggesting that endogenous HO-1 expression does not modulate the expression of these 
molecules during DC maturation. Because mice from Hmox1 deficient colony have to be 
Figure 4.  Activation of 
MOG35-55 loaded DCs by LPS. 
(A) FACS analysis of Hmox1+/+ 
DCs loaded with MOG35-55 
peptide (100 µg/ml; 4-6h) and 
treated afterwards with LPS 
(1000 ng/ml; 24h) (black line) or 
left untreated (solid gray). DCs 
were stained for costimulatory 
molecules (CD40, CD80 and 
CD86), CD11c and with PI and 
analyzed by flow cytometry. (B) 
Cell death was assessed by PI 
staining.  Data is from one 
experiment. All values are %. 
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maintained by mating of heterozygous (Hmox1+/-) mice, yielding 2-3% Hmox1 deficient 
(Hmox1-/-) mice, only one animal was used per experiment, which does not allow for 
statistical analysis.  
Naïve 6 to 8 week-old female C57BL/6 mice (n=5) received 4 x 106 Hmox1+/+ or 
Hmox1-/- DCs (i.v. and i.p.). CFA and PTx were given as described in the previous 
experimental setting (see section 5.3.). Mice adoptively transferred with DCs from Hmox1+/+ 
or Hmox1-/- mice failed to develop EAE during the 30 days following the adoptive transfer. 
This led again to question the quality of the DCs preparation in terms of activating an 
immune response in vivo despite the observation that these DCs can activate anti-MOG35-55-
reactive TH cells in vitro. We decided to alter the protocol of DC generation in order to obtain 
a more pure population of DCs and with a higher yield and try to improve the system by 










5.6. MODIFIED PROTOCOL TO GENERATE HIGH NUMBERS OF HIGHLY PURE DCS  
To improve the quality of our DC preparations we have adapted an experimental protocol 
described by M.B. Lutz et al., allowing the generation of larger numbers of highly pure DCs 
from mouse BM cells (57) (see Material and Methods, section 8.3.2.). BM cells where 
cultured according to the schedule depicted on Fig. 7A. The MOG35-55 peptide was added to 
the cells only at day 9 instead of day 6 (see protocol # 2 in Material and Methods, section 
8.2.2.), during 4-6h before exposure to LPS for additional 24h. DCs were used at day 10 
after the beginning of the culture. FACS analysis demonstrated that purity of DCs was 
significantly increased, i.e. 80 to 90% of the cells expressed the CD11c+ marker (Fig. 7C), as 
compared to the 60% in the previous protocols (see Fig. 1B).  
Moreover, DC viability was also increased, i.e. 100 x 106 live cells/mouse as 
compared to the 60 x 106 live cells/mouse obtained at the end of differentiation period using 
previous protocol. The basal percentage of DCs (non-treated) expressing high levels of 
maturation markers, i.e. MHC class II, CD80, and CD86 was slightly increased with this 
setting (Fig. 6B), as compared with non-treated DCs derived using the previous protocol (Fig. 
4A) (data not shown). Presumably this was due to extra handling of DCs during the culture 
period, a phenomenon showed to promote DC maturation (61). Exposure to LPS induced DC 
Figure 5. Hmox1+/+ and 
Hmox1-/- DCs have similar 
phenotype upon treatment 
with LPS. FACS analysis 
comparing maturation of DCs 
derived from BM of Hmox1+/+ 
(upper row) and Hmox1-/- mice 
(lower row) non-treated (solid 
gray) or loaded with MOG35-55  
(100 µg/ml; 4-6h) and treated 
thereafter with LPS (1000 ng/ml; 




maturation as revealed by the increased percentage of cells expressing high levels of 
activation markers compared with non-treated DCs (44.4% vs. 8.74% for CD40; 64.9% vs. 
24% for MHC class II; 50.4% vs. 11.7% for CD80 and 65% vs. 15.6% for CD86). DCs (1, 2 or 
4 x 106) were adoptively transferred, i.v. and i.p., into 6 to 12 week-old C57BL/6 female mice 
(n=5 per group). The expectation being that, due to the increased purity of the culture (> 80% 
CD11c+), cells transferred would be mostly DCs and these should trigger the onset of EAE. 
However, EAE was still not induced in these mice. Modifications to the standard protocol are 













5.7. T CELL PROLIFERATION WITH THE MODIFIED PROTOCOL TO GENERATE DCS 
We went on to test the capacity of DCs, generated according to the modified protocol, to 
activate MOG35-55 specific TH cells in vitro as described in Materials and Methods, section 
8.4. DCs were derived as detailed (see section 5.6.) and exposed to MOG35-55 (1 to 100 
µg/ml; 4-6h). DCs were otherwise left untreated or stimulated with LPS (1000 ng/ml; 24h). TH 
cells were purified from inguinal and popliteal lymph nodes of mice immunized with MOG35-55 
emulsified in CFA as detailed in Materials and Methods (see section 8.4.1.). DCs and TH 
cells were cultured at different cell ratios (1:2.5 to 1:100; DC/TH respectively). TH cell 
proliferation was assessed 72h thereafter by 3H-thymidine incorporation. We tested a dose 
response of peptide in the different ratios and we found that MOG35-55-loaded DCs activated 
anti-MOG35-55-specific TH cells in a dose-dependent manner in that the maximal proliferation 
was obtained using the highest concentration of peptide (100 µg/ml) for the 1:5 ratio. This led 
to a 8-fold increase in TH cell proliferation compared to non-treated DCs at the same ratio (P 
= 0.0097). We then addressed how DC maturation after exposure to LPS could induce even 
higher proliferation of TH cells and we saw that for higher ratios the proliferation went down 
but for lower ratios, cpm values were very significantly higher compared with non-treated 
DCs (e.g. 1:40 ratio, P = 0.002). 
 
 
Figure 6. Prolonged culture 
until day 10 increases BM-
DC purity. (A) Scheme 
illustrating the schedule used 
to derive DC from BM to 
induce EAE (red arrow) and to 
use in in vitro assays (blue 
arrow).  (B) FACS analysis on 
day 10 showing the activation 
of DCs treated or not with 
LPS. Cells were stained as 
before. (C) Purity of BM-DC 
culture (> 80 % CD11c+). (D) 
Cell death. Data is from one 
experiment. All values are %. 
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Using the modified protocol, DC death, both in LPS treated and non-treated 
population was never higher than 10% and thus was considered to be neglectable (Fig. 6D). 
Given the above, DC death cannot explain the lower proliferation observed using DCs 
treated with LPS (1:5 ratio). 
TH cells alone (white bar) proliferated to the same extent as cells incubated with non-
treated DCs (1:2,5 ratio; P = 0.384) leading us to conclude that the effect afforded in 
proliferation was due to presentation of MOG35-55 to TH cells by DCs. In the positive control 
(striped bar), i.e. cells from lymph nodes loaded only with MOG35-55 peptide (100 µg/ml), 
there was a significant proliferation (16420 ± 7484 cpm) confirming that the immunization 
protocol induced the expansion of anti-MOG35-55-reactive TH cells and also that in order to 
proliferate in vitro, TH cells require the presence of DCs presenting the peptide. 
To summarize, we saw that LPS-treated DCs are more potent activators of TH cells 
but only in lower ratios, at least in vitro. We hypothesized that elevated numbers of DCs 
(higher ratios) fully activated and presenting the peptide could have induced TH cell anergy or 
death (62). Still, from this experiment we could not conclude that DCs derived with the 
modified protocol are more efficient APC leading to TH cell proliferation than the ones derived 
using standard protocol. 
Protocols used in the adoptive transfers of DCs into naïve wild-type C57BL/6 mice 




























Figure 7. TH cell 
proliferation and DC 
maturation (modified 
protocol). (A) Proliferative 
response of TH cells co-
cultured or not with MOG35-
55-loaded DCs (1, 10 and 
100 µg/ml; 4-6h) and 
treated afterwards or not 
with LPS (1000 ng/ml; 
24h). Results shown are 
mean ± SD from triplicate 
wells. FACS analysis 
confirming (B) Purification 
of CD4+ TH cells from 
draining lymph nodes of 
MOG35-55 immunized 
C57BL/6 mice (cells were 
stained with anti-CD4-PE) 
and (C) Expression of 
surface markers in 
MOG/LPS treated (color 
lines) and non-treated 
(solid gray) DCs. All FACS 
data is from one 




5.8. INDUCTION OF EAE WITH MOG35-55-LOADED DCS IN 2D2 TCR TRANSGENIC MICE 
In the previous assays, we investigated whether mature DCs could present the MOG35-55 
peptide and activate naïve anti-MOG35-55-reactive TH cells in a manner that would trigger the 
onset of EAE when adoptively transferred into naïve mice. In addition, we also tested 
whether HO-1 expression in DCs modulated TH activation and/or effector function by leading 
to induction of EAE. We found that under the experimental conditions used, adoptive transfer 
of DCs failed to induce EAE. One reason that might explain the inability of adoptively 
transferred DCs to trigger the onset of EAE in naïve mice could be that the number of TH cell 
clones that recognize MOG35-55 in naïve C57BL/6 mice is extremely low, though no extensive 
characterization was done so far. For another myelin antigen, PLP, auto-reactive T cell 
numbers in BALB/C mouse strain are 1/20000 CD4+ TH cells (63). To overcome this limitation 
we performed additional experiments using the myelin oligodendrocyte glycoprotein-specific 
T cell receptor (TCR) transgenic mice, 2D2, in the C57BL/6 background. Contrary to naïve 
mice, about 98% of T cells in the 2D2 transgenic mice express TCR that recognize 
specifically the epitope MOG35-55 (64). DCs were obtained by culturing BM cells from 
Hmox1+/+ or Hmox1-/- naïve C57BL/6 mice using experimental conditions described in detail 
in the Material and Methods (see protocol # 2, section 8.3.2.). DCs (Hmox1+/+ and Hmox1-/-) 
were loaded with MOG35-55 peptide (100 µg/ml; 4-6h), washed and adoptively transferred into 
2D2 mice, as described in detail in Materials and Methods (see section 8.3.3.). DCs were not 
treated with LPS believing that this could lead to increased death of the DCs reducing their 
viability. To assess the activation status of the DCs, flow cytometry analysis was performed 
(Fig.8).
No significant differences were found in the percentages of DCs expressing high levels of 
maturation markers after MOG35-55 loading between Hmox1+/+ vs. Hmox1-/- DCs (17.2% vs. 
22.2% for MHC class II, 23.6% vs. 25% for CD80, 4.65% vs. 7.14% for CD86 and 0.66% vs. 
0.4% for CD40). However, these percentages seemed lower when compared with DCs 
treated with LPS in previous assays (Fig. 7C). Both groups (Hmox1+/+ DCs, n=3 and Hmox1-/- 
DCs, n=4) were transferred with 1 x 106 DCs. PTx was administered i.v. on the day after. In 
this initial experiment, the mice receiving the DCs were not treated with CFA believing that it 
 
Figure 8. Expression of 
activation markers by DCs 
adoptively transferred into 
2D2 transgenic mice. 
Hmox1+/+ (upper row) and 
Hmox1-/- (lower row) DCs 
loaded (black line) or not 
(solid gray) with MOG35-55 
peptide (100 µg/ml) at day 9 
after differentiation from BM 
precursor cells, analyzed by 
flow cytometry at day 10. 
Data is from one experiment. 
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could lead to an exacerbated immune reaction that might culminate in immediate death and 
so the animals were injected only with PTx. However, even using the 2D2 mice as recipients, 
adoptive transfer of DCs failed to promote the onset of EAE in these mice. We hypothesized 
that i) the absence of maturation 
stimulus (LPS and/or CFA) could 
explain the failure to induce EAE 
given that DCs need to be 
activated in order to prime TH cells 
and elicit an immune response 
and ii) that the number of DCs 
adoptively transferred (1 x 106) 
was low and could not be 
sufficient to trigger TH cell 
activation in a manner that would 
lead to disease development. We 
decided next to do a pilot 
experiment using a higher number 
of DCs (10 x 106) loaded with 
MOG35-55 (100 µg/ml; 4-6h) and 
treated with LPS (1000 ng/ml; 
24h). Contrary to the last experiment, this time we transferred Hmox1-/- DCs and added the 
adjuvant CFA only to assess if in these conditions mice would develop EAE. DCs were 
adoptively transferred i.v. into 6 to 8 week-old 2D2 mice (n=2) and PTx was injected i.v. on 
the day after. From day 9 post adoptive transfer, clinical signs of EAE were apparent in one 
out of two animals. Mice were followed during 30 days and the peak disease score was 3 
but, again, since only two animals were available for this experiment this did not allow us to 
reach a conclusion. Also, we went on testing to what extent the appearance of the clinical 
signs of EAE could be due to the adoptively transferred DCs or if the CFA and/or PTx could 
have afforded the same effect given that the animals were more prone to disease 
development (see Introduction, section 3.2.1.1.). To test these possibilities, two groups of 
mice (n= 3) were tested, one was treated only with CFA and PTx (control) without DCs 
transfer and the other was adoptively transferred with 10 x 106 MOG35-55-loaded (100 µg/ml; 
4-6h) and LPS-treated (1000 ng/ml; 24h) Hmox1+/+ DCs, along with CFA and PTx. Flow 
cytometry analysis showed that the percentage of DCs expressing high levels of maturation 
markers was increased when DCs were treated with LPS, i.e. CD86 (75.8% vs. 18.4% in 
controls), CD40 (25.2% vs. 5.93% in controls) and MHC class II (68.2% vs. 50.1% in 
controls). Nine days after adoptively transferring the DCs, we started observing clinical signs 
of EAE in one animal from the group that received the DCs. Two days after, however, one 
   
Figure 9. Induction of EAE in 2D2 TCR transgenic mice. Mice were 
adoptively transferred (filled circles z; n=3) or not (open circles {; n=3) 
with Hmox1+/+ DCs (10 × 106) loaded in vitro with MOG35-55 (100 μg/ml; 4-
6h) before LPS (1000 ng/ml; 24h). Mice received CFA (100 µl/flank; s.c.) 
and PTx (300 ng; i.v.) one day later. Mice were assessed daily for clinical 
signs of EAE and scored on a scale of 1-5 as described in the Materials 




animal from the control group showed signs of disease as well. Just 1 out of 3 animals in 
each group developed symptoms of EAE. Peak disease score was 5 for the mice that 
received the DCs and 3 for mice from control group. Still, we could not compare the relative 
severity of disease between the two groups, given the small number of animals (n=3). Graph 
on Fig. 9 illustrates the course of disease in both groups (mean clinical score). Although mice 
transferred with MOG35-55-loaded DCs developed symptoms of EAE earlier and with a more 
severe outcome than mice from the group that received only the CFA and the PTx, more 
experiments to confirm this and to test our main hypothesis should be done. In confirming 
these results one could reason that this is probably due to the fact that adoptive transfer of 
DCs leads to activation of a higher number of MOG35-55-specific TH cells and faster since DCs 
are already presenting the peptide. In contrast, using only CFA and PTx, DCs are activated 
in vivo and only then they migrate to lymph nodes where they interact with anti-MOG35-55-
reactive TH cells. Protocols used for EAE induction in 2D2 TCR Tg mice are summarized in 



























6. DISCUSSION AND FUTURE PERSPECTIVES 
Several lines of evidence suggest that HO-1 expression has protective effects during the 
course of EAE (52, 56). Hmox1-/- mice have a more severe disease outcome when compared 
to Hmox1+/+ mice (52). Pharmacological induction of HO-1 inhibits the development of EAE, 
an effect associated with inhibition of the proliferation and effector function of myelin-reactive 
T cells in the CNS (52). In vitro analysis suggests that this mechanism is mediated via DCs 
expressing high levels of HO-1 (52).  
The role of DCs in the initiation of EAE has been previously shown (65). The biologic 
function of HO-1 expression in DCs however, remains elusive. Whether HO-1 expression 
decreases DC immunogenicity, such as by impairing their capacity to trigger effector TH cell 
responses and/or whether it increases the tolerogenic properties of DCs, e.g. promoting the 
generation of TH cells with regulatory properties, remains to be tested.  
To assess whether expression of HO-1 in DCs could account for its ability to 
suppress the onset of EAE we set-up an experimental system in which adoptively transferred 
DCs would trigger the development of EAE. DCs were “loaded” with the MOG35-55 peptide 
and adoptively transferred into naïve mice. The expectation being that DCs would activate 
anti-MOG35-55-reactive TH cells, leading to the development of EAE. This effect should be 
exacerbated when DCs do not express HO-1, i.e. derived from Hmox1-/- mice. However, 
there are some limitations to this approach. First the need to set-up the experimental assay 
leading to the onset of EAE. Second the difficulty in generating Hmox1-/- mice on the 
C57BL/6 background (see Material and Methods, section 8.1.1.).  
We first tried to induce disease in naïve wild-type mice using MOG35-55-loaded DCs. 
We used several permutations on the experimental protocol, such as by improving purity of 
DCs (see Fig. 6C in Results) and by transferring higher numbers of DCs via different routes 
(i.v. and i.p.). In all cases adoptively transferred DCs failed to induce the onset of EAE in 
naïve mice. When tested in vitro, though, DCs were capable of inducing proliferation of anti-
MOG35-55-reactive TH cells (see Fig. 3B in Results). These results led us to reason that 
deletion of HO-1 might increase DC immunogenecity to prime TH cells in vivo as to trigger 
EAE. However, we found that DCs from Hmox1-/- also failed to induce EAE upon adoptive 
transfer into naïve mice. This might be explained in different ways. First, upon adoptive 
transfer, DCs are rapidly eliminated by NK and/or TC cells (66), thus impairing priming of 
MOG35-55-reactive TH cells as to promote the onset of EAE. To overcome this we adoptively 
transferred up to 10 times higher number of DCs (see Results, section 5.4.) but again, DCs 
failed to promote the onset of EAE.  
A second possibility to explain the inability of DCs to trigger the onset of EAE might 
be that the DCs might not migrate to the specific sites, i.e. lymph nodes or spleen, as to 
trigger TH cell activation and promote the onset of EAE. In our experiments, we only 
transferred DCs i.v. and i.p. thinking that they would home to the spleen and then activate a 
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sufficient level of TH cells as to trigger the onset of EAE. It has been shown that when 
administered subcutaneously, adoptively transferred DCs home preferentially to T cell areas 
in draining lymph nodes, as compared to DCs administered intravenously or intraperitoneally 
(see Results, section 5.4.), that accumulate in the spleen and in visceral lymph nodes 
respectively (67, 68). Since TH cells must be activated in peripheral lymph nodes as to 
migrate into the CNS and trigger EAE, it might be that when administered subcutaneously, 
DCs will be able to do so (69).  
A third possibility to explain the inability of adoptively transferred DCs to trigger the 
onset of EAE could be that these DCs might not be immunogenic as to activate T cells 
efficiently in vivo. Since DCs used in these adoptive transfer experiments were shown to 
induce TH cell proliferation in vitro we assumed that the same should occur in vivo. However, 
in the in vitro assays DCs interact with TH cells that had been primed in vivo, i.e. they elicit a 
secondary T cell activation given that the mice have already been immunized with the 
peptide which induced activation and subsequent proliferation of TH cells while adoptively 
transferred DCs in vivo interact with naïve TH cells, i.e. eliciting a primary TH cell activation. 
Naïve and primed TH cells seem to require different activation signals to proliferate since their 
states of differentiation are distinct (70). It should also be noted that, even though EAE did 
not develop after DCs adoptive transfer, this does not necessarily means that self-reactive TH 
cells were not being activated in vivo. In other words, even though adoptively transferred 
DCs may lead to some level of TH cell activation this might not be translated in the 
development of EAE. This remains, however, to be tested such as by analyzing TH cell 
activation in vivo. If one would find that these DCs can only activate primed TH cells then an 
alternative experimental system would be to co-transfer the DCs with self-reactive TH cells 
that have been previously activated ex vivo or to prime TH cell in vivo and only then transfer 
the DCs. 
A fourth possibility to explain the inability of adoptively transferred DCs to trigger the 
onset of EAE could be that naïve mice have very low numbers of naïve MOG35-55-specific TH 
cell number. According to this notion, the chances of adoptively transferred DCs to encounter 
a specific TH cell in vivo are extremely low, thus decreasing significantly chances that the 
DCs would ever be able to activate a sufficient number of TH cell clones as to trigger the 
onset of EAE. To overcome this possibility, we made use of the myelin oligodendrocyte 
glycoprotein-specific T cell receptor (TCR) transgenic mice, i.e. 2D2. These mice express a 
TCR that recognizes specifically the MOG35-55 peptide. These transgenic T cells represent 
about 98% of CD3, i.e. T cells in the periphery (64). These mice allow testing whether failure 
to induce EAE upon adoptive transfer of DCs is due to the very low frequency of anti-MOG35-
55 TH cells in wild-type C57BL/6 mice. However, DCs where rather inefficient in triggering the 
onset of EAE even when adoptively transferred into these transgenic mice. These 
experiments were performed using very low number of animals and for that reason the 
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results need to be further confirmed. We found that one naïve 2D2 mouse, out of three, 
developed EAE when transferred with Hmox1+/+ DCs along with CFA and PTx (Fig. 9 in 
Results). Similar results were obtained using Hmox1-/- DCs (data not shown). However, we 
also found that, when treated with CFA and PTx, one 2D2 mouse out of three also developed 
EAE (see Fig. 9 in Results). The onset of disease seemed to occur earlier in the group 
receiving DCs and the clinical outcome was more severe, as compared to mice that did not 
receive DCs. Even though it is difficult to reach a conclusion based on the small number of 
animals analyzed, this data would suggest that even in 2D2 mice where 98% of naïve T cells 
recognize MOG35-55, adoptively transferred DCs are not able to trigger the onset of EAE. This 
excludes the possibility of low number of anti-MOG35-55 clones being the reason why DCs are 
unable to trigger the disease after adoptive transfer. It is likely therefore that inability of DCs 
to trigger EAE after adoptive transfer requires either that DCs localize specifically to the T 
cell areas in the lymph nodes avoiding cell death as well as TH cell in the recipient mice to be 
previously primed. These possibilities remain to be tested experimentally and the role of 
expression of HO-1 in DCs during this process to be determined. 
7. CONCLUDING REMARKS  
Over this year we have attempted to develop an experimental system to test whether 
expression of HO-1 in DCs could activate self-reactive TH cell as to trigger the onset of EAE. 
However, this system needs to be further optimized in a way as to induce EAE and allow 
testing specifically the effect of HO-1 expression in DCs in the outcome of this disease. 
Based on the results obtained, we were not able to provide evidence that HO-1 in MOG35-55-
presenting DCs promotes an inflammatory TH cell phenotype that prones these cells to 
trigger the onset of EAE. Therefore this hypothesis remains to be tested. MS and its 
experimental counterpart, i.e. EAE, are complex diseases that involve the participation of 
many cell types besides peripheral DCs. Besides the peripheral lymphoid organs, self-
reactive TH cells can encounter competent DCs in the CNS and become reactivated as to 
promote the onset of disease. Thus we should not discard the role of HO-1 expression in 
CNS resident DCs and microglia in the reactivation of self-reactive T cells in the CNS. 
Whether immunity vs. tolerance to a given antigen is induced in this type of setting seems to 
be a multifactorial phenomenon that still needs to be understood and the conditions 








8. MATERIALS AND METHODS 
8.1. MICE 
8.1.1. GENERATION OF MICE  
Animals were maintained under specific pathogen free conditions approved by the Animal 
User and Institutional Ethical Comities of the Instituto Gulbenkian de Ciência. During the 
experiments, no significant differences were observed between males and females, therefore 
mice from both genders were used. C57BL/6 mice were obtained from the Instituto 
Gulbenkian de Ciência. C57BL/6 Hmox1+/- mice were originally generated by Shaw-Feng Yet 
(71) (Pulmonary and Critical Care Division, Brigham and Women's Hospital, Boston, MA, 
USA), in which targeted mutation replaced HO-1 exon 3 by a neomycin resistance cassette. 
C57BL/6 Hmox1+/- mice were intercrossed at the Instituto Gulbenkian de Ciência to generate 
Hmox1-/- homozygotes yielding 2-3% of Hmox1-/- mice. For this reason, few mice were 
available for this thesis. Littermate Hmox1+/+ mice were used as controls in all experiments. 
 C57BL/6 2D2 TCR transgenic mice were generated by Estelle Bettelli (64) (Center for 
Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, 
MA) and were kindly provided by Dr. Erick Duckers (Erasmus MC – Medical Center, 
Rotterdam University, Rotterdam, Holland). C57BL/6 2D2 TCR transgenic mice express a 
mouse alpha-chain (Valpha3.2) and beta-chain (Vbeta11) T cell receptor that pairs with the 
CD4 coreceptor and is specific for myelin oligodendrocyte glycoprotein peptide residue 35 to 
55 (MOG35-55). 2D2 Tg mice had to be kept in the quarantine and several trials to rederive 
them into the clean section were performed although never successfully. At the clean 
section, the colony could have been expanded contrary to the quarantine were the space is 
limited and only the original strains can be maintained. For this reason few mice were 
available for this thesis.  
8.1.2. GENOTYPING 
Offspring from Hmox1+/+ mating was genotyped by PCR. Briefly, genomic DNA was isolated 
from the tail and amplified using the following primers: 5’ TCT TGA CGA GTT CTT CTG AG 
3’ and 5’ ACG AAG TGA CGC CAT CTG T 3’; 5’ GGT GAC AGA AGA GGC TAA G 3’ and 5’ 
CTG TAA CTC CAC CTC CAA C 3’. The first set amplifies a 400-base pair fragment 
equivalent to the mutated allele. The second set amplifies a 456-base pair fragment 
corresponding to the wild-type allele.  
Routine screening of progeny, to identify 2D2 transgenic mice, was also performed by 
PCR using DNA isolated from tail using Vα3.2 (5’ CCC GGG CAA GGC TCA GCC ATG CTC 
CTG 3’) and Jα18 (5’ GCG GCC GCA ATT CCC AGA GAC ATC CCT CC 3’) primers 





8.2. MEDIUM AND REAGENTS 
Iscove’s Modified Dulbecco’s Medium (IMDM) or Roswell Park Memorial Institute (RPMI-
1640) medium (Invitrogen life technologies, Gibco, Grand Island, NY, USA) was 
supplemented with 5% or 10% of heat-inactivated fetal calf serum (FCS) respectively. The 
FCS was tested for dendritic cells (DCs) generation giving low basal expression of activation 
markers and high activation upon maturation stimuli. Culture medium was further 
supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin (P/S), 50 μM 2-
mercaptoethanol (2-ME), 10 mM Hepes, and 1 mM sodium pyruvate (all Invitrogen 
Corporation, Gibco). 
To produce granulocyte macrophage-colony stimulating factor (GM-CSF) first J558 
cells, hybridoma originated from BALB/c, were cultured in D-MEM: F12 (GibcoBLR) 
supplemented with 10% fetal bovine serum (FBS) (GibcoBRL), 2% P/S, 2% L-glutamine 
(Sigma), 2-mercaptoethanol and G418 (Geneticin at 1 mg/ml). Confluent cells were 
transferred to a T150 flask (TPP® Techno Plastic Products AG) and grown in 50 ml of 
medium without Geneticin for 3 days, which is an antibiotic that also represses transcription 
from the GM-CSF promoter inhibiting its production and secretion to the medium. Cell 
suspension was collected, centrifuged (200g, 10 min at 4ºC) and supernatant filtered through 
0.22 μm and used in 1% concentration to culture and differentiate DCs from bone marrow 
(BM) hematopoietic progenitors. 
The myelin oligodendrocyte glycoprotein peptide (MOG35-55) corresponds to 
aminoacid residues 35 to 55 of the mouse sequence (MEVGWYRSPFSRVVHLYRNGK) and 
was synthesized at the Biopolymers Laboratory of Harvard Medical School. MOG35-55 was 
dissolved in sterile (1X) phosphate-buffered saline ((PBS), Gibco) at the final concentration 
of 2 mg/ml. Aliquoted stocks were stored at -20ºC until use. 
8.3. DENDRITIC CELLS 
8.3.1. GENERATION OF BONE MARROW-DENDRITIC CELLS (BM-DC)  
Naïve C57BL/6 Hmox1+/+ and Hmox1-/- mice, 6 to 12 week-old, were sacrificed and rinsed 
with ethanol 70ºC. Previously sterilized scissors and forceps were used to do a small incision 
in the fur of the back and “undress” the mice completely until the legs were left with muscle-
only. The muscles were removed from the legs with the help of scissors and forceps until the 
bones were exposed. A cut in the joints was done at the upper part of the femur and lower 
part of tibiae. Bones were placed in a 6-well plate (TPP® Techno Plastic Products AG) with 
(1X) PBS supplemented with 2% heat inactivated FBS on ice. After this point, all procedures 
were performed under sterile conditions, inside a cell-culture hötte. The BM was flushed out 
of the two femurs and tibiae using a 1 ml syringe with a 25G needle (TERUMO, Leuven, 
Belgium) filled with pre-warmed culture medium and collected with the help of forceps into a 
6-well plate also containing medium. Cells were resuspended gently until a single cell 
suspension was obtained and collected into a 15 ml Falcon tube (TPP® Techno Plastic 
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Products AG). The cell suspension was placed on ice until the debris precipitated at the 
bottom and then decanted into a new 15 ml falcon tube and centrifuged (200g, 10 min at 
4ºC). Supernatant was discarded and the cells were gently resuspended in culture medium, 
seeded into 100 mm Petri dishes (TPP® Techno Plastic Products, AG) at the final 
concentration of 6 x 106 cells per plate in a total of 12 ml of complete IMDM or RPMI-1640 
medium supplemented with 1% GM-CSF. BM cell numbers were determined by light 
microscope using a haemocytometer (improved Neubauer type, BLAU BRAND). Cells were 
stained with 1 vol. of trypan blue solution (0.4 %, Sigma) to exclude dead cells (stained blue) 
and cell number was calculated by multiplying the average number of cells counted in two 
haemocytometer fields (20 squares each) per 104. Cells were grown at 37 ºC in cell culture 
incubator with 95% humidity supplemented with 5% CO2. 
8.3.2. MEDIUM REPLACEMENT AND EXPOSURE OF DCS TO PEPTIDE 
Protocol # 1 – Cells were isolated from BM as described in section 8.3.1. and cultured in 
IMDM as described in section 8.2. Culture medium was exchanged every two days by 
replacing half volume by new medium supplemented with freshly added 1% GM-CSF as 
described in section 8.2.1. At day 6 or 7, cells were loaded with MOG35-55 peptide at several 
concentrations (1, 10 or 100 μg/ml; for 4-6h). Control cells were not exposed to MOG35-55, i.e. 
not loaded. At day 7, non-adherent cells were collected and washed twice in (1X) PBS to 
eliminate excess of MOG35-55 peptide by centrifugation (200g, 5 min at 4ºC). Cells were 
counted as described before (see section 8.3.1.) and resuspended in either (1X) PBS for 
adoptive transfers into mice or in RPMI for in vitro assays, at the intended final 
concentrations. 
Protocol # 2 – Cells were isolated from BM as described in section 8.3.1. and cultured in 
RPMI medium as described in section 8.2. At day 3, 12 ml of fresh and pre-warmed medium 
supplemented with freshly added 1% GM-CSF were added to the plates. At days 6 and 8, 
half volume of the culture medium was collected, centrifuged (200g, 5 min at  4ºC), the cell 
pellet resuspended in 12 ml of fresh medium supplemented with 1% GM-CSF and returned 
to the original plate. At day 9, cells were loaded with MOG35-55 peptide at several 
concentrations (1, 10 or 100 μg/ml; 4-6h). Control cells were not exposed to MOG35-55, i.e. 
not loaded. At day 10, non-adherent cells were collected and washed twice in (1X) PBS to 
eliminate excess of MOG35-55 peptide by centrifugation (200g, 5 min at 4ºC). Cells were 
counted as described before (see section 8.3.1.) and resuspended in either (1X) PBS for 
adoptive transfers or in RPMI for in vitro assays, at the intended final concentrations. 
When appropriate, the maturation stimulus lipopolysaccharide (LPS from S. 
Typhimurium, batch 083K4114 (Sigma)), prepared in (1X) PBS, was added to DCs, at 
different concentrations 0.1, 1, 10, 100 and 1000 ng/ml, for 24 or 48h before cells were 
harvested for analysis.  
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8.3.3. INDUCTION OF EAE WITH DCS  
6 to 8 week-old female C57BL/6 mice were pre-heated under a red lamp until the tail veins 
dilated and became visible. Mice were injected intravenously (i.v.) in the tail vein and/or 
intraperitoneally (i.p.) with MOG35-55-loaded (100 µg/ml) and LPS-treated (1000 ng/ml) 
Hmox1+/+ or Hmox1-/- DCs in a range of concentrations from 5 x 105 to 80 x 105 cells at the 
final volume of 200 µl/mice. Complete Freund’s adjuvant ((CFA) Difco Laboratories) 
supplemented with heat-inactivated Mycobacterium tuberculosis (400 μg; BD Diagnostics) 
was injected subcutaneously (s.c.) (100 µl/flank) at the same day. One day after adoptive 
transfer of the DCs, Pertussis toxin ((PTx) Sigma-Aldrich Química) diluted in (1X) PBS was 
administered i.v. via the tail vein (300 ng in 100 μl). From day 7 upon adoptive transfer of the 
DCs, mice were followed daily and scored for clinical signs of EAE according to the following 
criteria: 0, no disease; 1, decreased tail tone; 2, hind limb weakness or partial paralysis; 3, 
complete hind limb paralysis; 4, front and hind limb paralysis; 5, moribund state. 
C57BL/6 2D2 TCR transgenic male and female mice, 6 week- to 7 month-old were 
pre-heated under a red lamp until the tail veins dilated and became visible.  Mice were 
injected i.v. in the tail vein with 1 x 106 or 10 x 106 MOG35-55-loaded Hmox1+/+ or Hmox1-/- DCs 
and treated or not with LPS (1000 ng/ml). CFA was injected at the same day or excluded. 
One day after adoptive transfer of the DCs, PTx was administered i.v. (300 ng of PTx in 100 
μl of (1X) PBS). From day 2 after DC transfer, mice were followed daily and scored for 
clinical signs of EAE according to the previously described criteria. 
8.4. T CELLS 
8.4.1. EXPANSION OF T CELLS IN VIVO  
In order to expand the population of MOG35-55-specific TH cells, we promoted proliferation of 
these cells in vivo in 6 to12 week-old C57BL/6 wild-type mice. MOG35-55 peptide in a final 
concentration of 2 mg/ml diluted in (1X) PBS was emulsified in CFA supplemented with heat-
inactivated Mycobacterium tuberculosis (400 µg) and injected in a total of 50 μl of emulsion 
per footpad. 
8.4.2. ISOLATION AND PURIFICATION OF CD4+ TH CELLS  
Peripheral draining lymph nodes were harvested 7 days after footpad immunization. Mice 
were sacrificed, rinsed with ethanol 70% and scissors and forceps were used to cut the skin 
along the ventral midline from the chest to the groin. A first incision was made in the chest 
area until the groin and from that a second incision was made to down near the knee on both 
sides of the animal. The skin was retracted on both sides. Inguinal and popliteal lymph nodes 
were collected and placed in a cell culture plate containing (1X) PBS with 2% FBS on ice. 
Lymph nodes were disintegrated under sterility conditions using a nylon mesh in a 6-well 
plate containing (1X) PBS 2% FBS. A single cell suspension was obtained by pipetting and 
collected into a 15 ml Falcon tube kept on ice. Debris were allowed to precipitate, cells were 
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decanted into a falcon tube and centrifuged (200g, 5 min at 4ºC). The supernatant was 
discarded, cells were resuspended in 10 ml of (1X) PBS 2% FBS and counted under the 
microscope (see section 8.3.1). FACS data shows that, upon activation in vivo, CD4+ TH cells 
represent about 30% of total lymph nodes cells (data not shown). Cells were centrifuged 
again (200g, 5 min at 4ºC) and resuspended in (1X) PBS 2% FBS at a final concentration of 
10 x 106 CD4+ TH cells/ 100 µl considering that 30% of the counted cells were CD4+ TH cells. 
As a positive control for cell proliferation, before isolating CD4+ TH cells, an aliquot of 
total lymph node suspension was seeded in triplicate in a flat bottom 96-well plate in a way 
that each well had a density of (theoretically) 100 x 103 CD4+ TH cells in 200 µl complete 
RPMI. Cells were exposed to MOG35-55 peptide in a final concentration of 100 μg/ml for 72h. 
Since we aimed at assessing the proliferation of CD4+ TH cells, first they needed to be 
isolated from the single-cell suspension obtained from desintegration of the lymph nodes that 
contain also non-CD4+ TH cells. We used a magnetic bead-based cell separation system that 
allows for either positive selection as well as negative selection of labeled cells. 
To isolate CD4+ TH cells from lymph nodes single cell suspension, first 10 µl of anti-
CD4 (L3T4) MicroBeads (Miltenyi Biotec) which are antibodies against CD4 conjugated with 
magnetic beads, were added per 107 cells and the tube was kept in the dark and on ice for 
20 min. Cells were washed (15 ml with (1X) PBS 2% FBS) and excess antibodies removed 
after centrifugation (200g, 5 min at 4ºC). Supernatant was discarded and cells resuspended 
in 3 ml (1X) PBS 2% FBS and applied on a MidiMACS magnetic isolation system (Miltenyi 
Biotec). Magnetically labelled cells (that express CD4high) are retained on the column and 
separated from non-labelled cells, which pass through. Briefly, a 25LS column was hold in 
the magnet and a 15 ml falcon tube was placed under the column. Column was washed with 
(1X) PBS 2% FBS, cell suspension was loaded into the column and then the column was 
further washed (3 times with buffer (1X) PBS 2% FBS) to remove unlabelled CD4 negative 
cells. The column was removed from the magnet and placed in a clean 15 ml falcon tube, 
loaded with (1X) PBS 2% FBS (5 ml) and rinsed using a plunger, allowing to collect the CD4 
positive (retained) fraction. Purity of selection was assessed by flow cytometry (see section 
8.5). 
8.4.3. ANTIGEN PRESENTATION ASSAY 
CD4+ TH cells fraction was counted under the microscope (see section 8.3.1.) in a 1:10 
dilution in trypan blue.  A cell suspension of 1 x 106 cells/ml was prepared in complete and 
pre-warmed RPMI and cells were seeded at a density of 100 x 103 per 100 μl of RPMI  per 
well in a round bottom 96-well plate. BM derived cells, mainly DCs as assessed by FACS 
analysis (see Results, Figs. 1 and 6), unloaded or loaded with different concentrations of 
MOG35-55 peptide (1, 10 or 100 µg/ml) and treated with LPS (10, 100 or 1000 ng/ml) were 
added at different DC to CD4+ TH cells ratios (from 1:1 to 1:160) to the seeded CD4+ TH cells 
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in a final volume of 200 μl of culture medium (RPMI). Cells were grown in the previously 
described conditions for 72h (see section 8.3.1.). 
8.4.4. MEASUREMENTS OF T CELL PROLIFERATION  
Tritium is the only radioactive isotope of hydrogen. It decays with a half-life of 12 years by 
emitting a beta particle to produce helium-3. Beta particles are high-energy, high-speed 
electrons or positrons emitted by certain types of radioactive nuclei. [3H]-thymidine acts by 
getting incorporated into the newly synthesized DNA of the dividing cells. In order to evaluate 
CD4+ TH cell proliferation, cells were loaded with [3H]-thymidine (1μCi/well) (GE HealthCare) 
72h after incubation of DCs with CD4+ TH cells. Incoportaion of [3H]-thymidine by CD4+ TH 
cells was stoped 6h thereafter by freezing the plate at -20 ºC. To measure [3H]-thymidine 
incorporation cells were thawed and harvested (Tomtec, Pharmacia & Upjohn, Portugal) onto 
a filter (Printed Filtermat A, Wallac Oy, Turku, Finland). Scintillation fluid sheets were melted 
over the filters to amplify the β-emission (Melt-on Scintillator Sheets, PerkinElmer life 
sciences, Wallac Oy, Turku, Finland). Measurements were done using a β-counter (1450 
Microbeta Liquid Scintillation Counter, Pharmacia & Upjohn, Portugal). The amount of 
radioactivity incorporated into DNA is proportional to the number of proliferating cells, which 
in turn is a function of the number of lymphocytes that were stimulated by the DCs to enter 
the proliferative response. The readout is counts per minute (cpm) per well. The radioactive 
material was handled according to the Instituto Gulbenkian de Ciência radiation safety rules 
and following the standard operating procedures for tritium. 
8.5. FLOW CYTOMETRY ANALYSIS 
Cell stainings were performed in FACSCalibur (Becton Dickinson, S.A. Spain, Madrid) and 
the data obtained analyzed with FlowJo (Tree Star) software. Briefly, for DCs stainings, cells 
were left for 7 days (see protocol #1, section 8.3.2.) or 10 days (see protocol #2, section 
8.3.2.) in culture. After the time of culture, 200 μl samples were collected from each 
treatment condition into a round bottom 96-well plate, cells were washed in FACS buffer 
((1X) PBS with 2% FBS) by centrifuging (800g, 2 min at 4ºC) and pre-incubated with 50 
μl/well of unlabelled mouse antibody specific to the FC-gamma receptor (Anti-FcγIII/II, clone 
2.4G2 produced at the Instituto Gulbenkian de Ciência) for 15 min, after which cells were 
washed again with FACS buffer (800g, 2 min at 4ºC). DCs express Fc receptors that can 
bind to Fc regions of antibodies, used to stain other molecules, which can generate non-
specific staining. Fc block is an antibody that binds to these receptors and avoids unspecific 
binding. Antibody mix (40 μl) was incubated for 20-30 min in the dark and on ice. All samples 
were stained with CD11c to allow the identification of DC population. Additionally, cells were 
stained either with CD40 and I-Ab (MHC-II) or with CD80 (B7-1) and CD86 (B7-2) (all BD 
Bioscience) (see supplementary Table 5 in Annex, Material and Methods) to assess the 
activation state. After incubation with the antibodies, cells were washed with FACS buffer 
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and the streptavidin-APC conjugate (BD Biosciences) was added for 20-30 min in the dark 
and on ice. After washing with FACS buffer (800g, 2 min at 4ºC), cells were resuspended in a 
solution of FACS buffer (150 μl) containing propidium iodide (PI) (50 μl). PI is an intercalating 
and fluorescence molecule that is membrane impermeant and generally excluded from viable 
cells. It is commonly used to identify dead cells in a population and as a counterstain in 
multicolor fluorescent techniques. Acquisition of the samples was performed by excluding 
dead cells as being positive for PI staining. Expression of CD40, MHC class II, CD80 and 
CD86 was analysed inside the CD11c positive population (DCs). First, cells were analysed 
regarding forward scatter FSC (size) and side scatter SSC (granularity) in order to exclude 
cellular debris that display smaller size and lower granularity. Cells were gated and analyzed 
for CD11c expression excluding dead cells (PI+). CD11c positive population was then 
analyzed for expression of activation markers. CD40 and CD86 were labeled with FITC 
(Fluorescein isothiocyanate), MHC class II and CD80 with biotin and CD11c with PE 
(Phycoeritrin).  
The purity of CD4+ TH cells was evaluated by removing a sample from both positive 
and negative fraction of CD4 T cells, collect them into a round bottom 96-well plate, 
centrifuge (800g, 2 min at 4ºC), discard the supernatant and incubating cells with 50 μl of 
anti-mouse CD4 conjugated with PE (BD Bioscience) for 20-30 min in the dark and on ice. 
After this incubation step, cells were washed and resuspended in 150 μl of FACS buffer. 
Cells were analysed for expression or not of surface marker CD4 inside the whole population 
of cells that displayed the right size and granularity chosen in FSC vs. SSC gate.  
8.6. STATISTICAL ANALYSIS 




1. FACS Buffer – (1X) PBS, 2% FBS. 
2. LPS – LPS from Salmonella typhimurium, batch 083K4114 from Sigma, was diluted 
in sterile (1X) PBS for a stock concentration of 10 mg/ml. Aliquots were stored at -
20ºC before use. For the experiments, further dilutions were made in sterile (1X) PBS 
for the intended final concentrations. 
3. Phosphate-buffered saline (PBS) – 2.6 mM KCL, 17.6 mM KH2PO4, 137 mM NaCl, 
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11. ANNEX  
 




























Supplementary Table 3. EAE induction protocols tested in naïve wild-type C57BL/6 mice. 
Experiment No. Treatment  n Incidence of EAE 
1 
CFA + PTx 5 0/5 
6 x 105 DC + CFA + PTx 5 0/5 
12 x 105 DC + CFA + PTx 5 0/5 
2 1, 2 or 4 x 106 Hmox+/+ DC(iv + ip) + CFA + PTx 5 0/5 
3 1, 2 or 4 x 106 Hmox-/- DC( iv + ip) + CFA + PTx 5 0/5 
4 1, 2 or 4 x 10
6 DC(iv + ip) + CFA + PTx (modified 
protocol) 5 0/5 
The clinical score for assessment of EAE is described in Materials and Methods (see section 8.3.4.). 
Supplementary Table 2. Comparison of two different protocols to generate DCs from BM precursor 
cells. 
 STANDARD MODIFIED 
Medium IMDM + 5% FCS RPMI-1640 + 10% FCS 
Medium Replacement 
Collect half of the volume of medium and 
add the same volume of new medium 
supplemented with GM-CSF every other 
day. 
Add medium on day 3 and collect ½ on days 
6 and 8, centrifuge, resuspend cells in new 
medium with GM-CSF and give back to 
original plates. 
MOG35-55 peptide On day 6 (4 to 6h before LPS) On day 9 (4h to 6h before LPS) 
LPS 48h  24h 
Culture Period 7 days 10 days 
DC Purity with  
1% GM-CSF 50-70 % 70-90% 
Supplementary Table 1. MOG35-55-loaded Hmox1+/+ DCs failed to induce EAE in naïve C57BL/6 mice upon 
adoptive transfer.  
Group No. Treatment n Incidence of EAE 
1  CFA + PTx 5 0/5 
2 6 x 105  DC + CFA + PTx 5 0/5 
3 12 x 105  DC + CFA + PTx 5 0/5 


















11.2. MATERIAL AND METHODS 




















Supplementary Table 4. EAE induction protocols tested in 2D2 TCR transgenic mice. 
Experiment 
No. Treatment n Incidence of EAE 
1 
1 x 106  Hmox1+/+ DC + PTx 4 0/4 




10 x 106  Hmox1-/- DC(LPS)  + CFA + PTx 2 1/2 
CFA + PTx 3 1/3 
10 x 106  Hmox1+/+ DC(LPS)  + CFA + PTx 3 1/3 
The clinical score for assessment of EAE is described in Materials and Methods (see section 8.3.4.). 
Supplementary Table 5. Combination of antibodies used to stain DCs (1 and 2) and CD4+ TH cells (3) 
before FACS analysis. 
FACS STAININGS 
1 2 3 
PI, 0.5 µg/ml PI, 0.5 µg/ml --------- 
PE mouse anti-CD11c, 
0.5 mg/ml 
(BD biosciences) 














(MHC-II), 0.5 mg/ml 
(BD biosciences) 




Anti-FcγIII/II (Fc block) Anti-FcγIII/II (Fc block) ---------- 
Streptavidin APC conjugate 
(BD biosciences) 
Streptavidin APC conjugate 
(BD biosciences) ---------- 
Anti-mouse I-Ab, CD40, CD86 and CD80 were used with a 1/400 dilution, anti-CD4, Fc block and Streptavidin 
APC in a final dilution of 1/100. PI was diluted 1/3 in the final sample from an initial 1/100 prepared aliquot. 
